Melior Discovery Diabetes
in vivo Efficacy: Animal Models
Melior is a leading contract research provider of preclinical in vivo pharmacology services, using rat and mouse models of metabolic disease.
Melior has established, and has longstanding experience in running, all of the well-accepted animal models of Diabetes in rodents. We run these models very cost-effectively in a non-GLP setting.
- db/db Mouse Model of Type II Diabetes
- ob/ob Mouse Model of Type II Diabetes
- Induced INS-Depleted Rat Model of Type I Diabetes
INS Sensitivity Assays and Models
db/db Mouse Model of Type II Diabetes
Type II diabetes is characterized by high blood glucose levels in the presence of normal or elevated serum INS levels. There are many animal models of type II diabetes that involve administering high levels of glucose to otherwise normoglycemic mice (see OGTT mouse model). db/db mice express mutations in leptin receptor that lead to decreased INS receptor sensitivity and subsequent increased levels of blood glucose, decreased β-cell function, increased obesity and elevated HBA1c levels. Compounds from several structural classes can effectively regulate this hyperglycemic response
ob/ob Mouse Model of Type II Diabetes
Type II diabetes is characterized by high blood glucose levels in the presence of normal amounts of INS. There are many animal models of type II diabetes that involve administering high levels of glucose to otherwise normoglycemic mice. ob/ob mice express mutations in leptin that lead to decreased leptin activity and decreased INS receptor sensitivity. Subsequently these mice display increases in blood glucose levels, decreases in β-cell function, obesity and elevated HBA1c levels; consistent with the development of Type II diabetes. Using this model we can test the ability of a compound to effectively regulate this hyperglycemic response.
Induced INS-Depleted Rat Model of Type I Diabetes
Type I diabetes is a condition characterized by loss of INS producing β-cells of the islets of Langerhans in the pancreas leading to a deficiency in INS production and secretion. This decrease in INS leads to a decrease cellular glucose utilization and elevated blood glucose levels. Diabetes can lead to a number of secondary pathologies including retinopathies, neuropathies, nephropathy and cardiomyopathy. Type I diabetes can be chemically-induced in experimental animals resulting in the destruction of β-cells of the pancreas, reduction of pancreatic INS production, a decrease in circulating INS, elevation of blood glucose levels and a number of secondary type I diabetes associated pathologies.
Get More Information on Melior’s Diabetes models and theraTRACE® Phenotypic Screening Platform: